Monopar Therapeutics Files 8-K
Ticker: MNPR · Form: 8-K · Filed: Jul 9, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Jul 9, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, regulation-fd
Related Tickers: MNPR
TL;DR
Monopar Therapeutics filed an 8-K on July 9th, likely with material updates. Check the full filing.
AI Summary
Monopar Therapeutics Inc. filed an 8-K on July 9, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details about the nature of the disclosure.
Why It Matters
This 8-K filing indicates that Monopar Therapeutics is making a disclosure under Regulation FD, which could pertain to material non-public information. Investors should review the full filing for details.
Risk Assessment
Risk Level: medium — The filing is an 8-K, which often contains material information, but the provided text lacks specific details about the nature of the disclosure, necessitating further review.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- July 9, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on a Regulation FD Disclosure and Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is July 9, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (847) 388-0349.
Under which section of the Securities Exchange Act is this report filed?
This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-07-09 16:01:43
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20240708_8k.htm (8-K) — 24KB
- ex_696110.htm (EX-99.1) — 10KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-022403.txt ( ) — 175KB
- mnpr-20240709.xsd (EX-101.SCH) — 3KB
- mnpr-20240709_def.xml (EX-101.DEF) — 12KB
- mnpr-20240709_lab.xml (EX-101.LAB) — 15KB
- mnpr-20240709_pre.xml (EX-101.PRE) — 12KB
- mnpr20240708_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 9, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging clinical trial of MNPR-101-Zr. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated July 9, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: July 9, 2024 By: /s/ Karthik Radhakrishnan Name: Karthik Radhakrishnan Title: Chief Financial Officer